Proactive Investors - Run By Investors For Investors

GSK warns 2018 earnings hinge on generic competition to its blockbuster Advair inhaler

If a generic competitor comes to market this summer as expected, GSK said earnings will fall by between 0-3%, while if a competitor isn’t forthcoming, earnings will rise by 4-7%
man using inhaler
Advair made more than £1.6bn in sales last year, but that could halve in 2018.

Increased competition in its core HIV and respiratory businesses could hit GlaxoSmithKline PLC’s (LON:GSK) earnings in 2018, the UK pharma giant warned on Wednesday.

At constant exchange rates, adjusted earnings per share grew 4% in 2017 to 111.8p, but GSK sees them flat to down 3% in 2018 if generic versions of its blockbuster Advair asthma treatment launch later in the year as expected.

READ: Barclays cites progress in HIV and new shingles vaccine as it turns bullish on GSK

US Advair sales could halve​

In the US, Advair generated sales of £1.6bn in 2017, but should competition from generics materialise, GSK reckons sales in the States will dive to around £750mln.

If a generic substitute doesn’t come on the market, the FTSE 100 drugmaker expects 2018 earnings to be rise by between 4-7%.

Despite the Advair uncertainty and looming competition from Gilead Sciences Inc’s (NASDAQ:GILD) rival HIV treatment, chief executive Emma Walmsley said she was “increasingly confident” her company could continue to deliver mid-to-high single digit earnings growth over the next few years.

Overall, the UK’s largest pharma outfit topped expectations with its fourth quarter results.

£1.7bn one-off tax hit​

GSK reported a fourth-quarter adjusted EPS of 27.2p, on sales of £7.64bn. According to Thomson Reuters, Wall Street had been expecting 26.0p and £7.49bn.

The London-based firm added it had taken a one-off tax charge of £1.7bn in its 2017 earnings as a result of the recently-introduced tax reforms in the US.

Going forward though, Glaxo expects the changes to lower its effective tax rate on underlying profits by two to three basis points.

The company declared a 23p dividend, amounting to a full-year pay-out of 80p, and backed its divi guidance, saying it continued to expect to pay out 80p again in 2018.

GSK shares edged 0.9% higher to £12.54 on Wednesday afternoon.

View full GSK profile View Profile

GlaxoSmithKline plc Timeline

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
January 25 2018
Interim results for a study on ezutromid revealed a “statistically significant and meaningful” reduction in muscle damage, the company said
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use